USPTO serial 79429249
CAUSEWAY – THE TENDON HEALTH COMPANY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MORRIS, KRISTINA KLOIBER
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with CAUSEWAY – THE TENDON HEALTH COMPANY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of tendinopathy; pharmaceutical preparations for the treatment of lateral epicondylitis (“tennis elbow”); pharmaceutical preparations for the treatment of rotator cuff tendinopathy; pharmaceutical preparations for the treatment of Achilles, gluteal, golfer's elbow, and patellar tendinopathies; pharmaceutical preparations for the treatment of conditions involving dysregulated collagen production; pharmaceutical preparations for the treatment of back pain; pharmaceutical preparations for the treatment of fibrosis; pharmaceutical preparations for the treatment of tendon stiffness; dietary and nutritional supplements; dietary and nutritional supplements for supporting treatment of tendinopathy, tendon stiffness, lateral epicondylitis (“tennis elbow”), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain | ACTIVE | — |
| 009 | Downloadable computer software and apps relating to the medical field for diagnosing, monitoring, and supporting the treatment of tendinopathy, tendon stiffness, lateral epicondylitis ("tennis elbow"), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain; recorded computer software and apps for diagnosing, monitoring, and supporting the treatment of tendinopathy, tendon stiffness, lateral epicondylitis ("tennis elbow"), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain | ACTIVE | — |
| 010 | Medical devices, namely, wearable therapeutic devices and electrical therapeutic devices for the treatment of tendinopathy, tendon stiffness, lateral epicondylitis ("tennis elbow"), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain; medical devices, namely, joint motion and pain monitoring devices; medical devices for the diagnosis, monitoring, and supporting the treatment of tendinopathy, tendon stiffness, lateral epicondylitis ("tennis elbow"), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain; wearable biometric monitors for the diagnosis, monitoring, and supporting the treatment of tendinopathy, tendon stiffness, lateral epicondylitis ("tennis elbow"), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain | ACTIVE | — |
| 042 | Research and development in the pharmaceutical and biotechnology fields; research and development in the fields of tendinopathy, tendon stiffness, lateral epicondylitis (“tennis elbow”), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain | ACTIVE | — |
| 044 | Medical diagnostic services; medical diagnostic services relating to tendinopathy, tendon stiffness, lateral epicondylitis (“tennis elbow”), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain; provision of medical information; provision of medical information relating to tendinopathy, tendon stiffness, lateral epicondylitis (“tennis elbow”), rotator cuff tendinopathy, Achilles, gluteal, golfer's elbow, and patellar tendinopathies, conditions involving dysregulated collagen production, fibrosis, and back pain | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Causeway Therapeutics Ltd
- Other trademarks owned by Causeway Therapeutics Ltd
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CAUSEWAY – THE TENDON HEALTH COMPANY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 28, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 28, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 23, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 22, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 8, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 26, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 26, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 26, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 26, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 26, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 5, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 5, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 5, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 8, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 8, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 8, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 30, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 8, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 8, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 21, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 20, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 8, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 8, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 31, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |